検索結果

論文投稿実績 | 研究開発活動 | 千寿製薬株式会社

and carcinogenicity evaluations of motugivatrep (SJP-0132) — a transient receptor potential cation channel subfamily V member 1 antagonist Kotaro Yamada1, Yoshinori Yamagiwa1, Hideya Yonekura1, Satok...

お知らせ | 千寿製薬株式会社

c suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） 2025年09月04日 Senju has developed and obtained approval f...

千寿製薬株式会社

c suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） 2025年09月04日 Senju has developed and obtained approval f...

ともご指導、ご厚情を賜ります ようお願い申しあげます。 謹白 製品名 アバレプト懸濁性点眼液0.3％ 一般名 モツギバトレプ ※Transient receptor potential cation channel subfamily V member 1 効能又は効果 ドライアイ ドライアイ治療剤 （TRPV1※ 拮抗薬）

千寿製薬株式会社

c suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） 2025年09月04日 Senju has developed and obtained approval f...